| 1.165 -0.075 (-6.05%) | 05-13 13:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.8 |
1-year : | 2.11 |
| Resists | First : | 1.54 |
Second : | 1.8 |
| Pivot price | 1.23 |
|||
| Supports | First : | 1.11 | Second : | 0.92 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.29 |
| MA(100) : | 2 |
MA(250) : | 5.13 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 23.2 |
D(3) : | 25.7 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 17.39 | Low : | 0.99 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FEED ] has closed above bottom band by 23.3%. Bollinger Bands are 83.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.21 - 1.21 | 1.21 - 1.22 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.
Wed, 04 Feb 2026
Envue Medical: Bank of America sells $8.9k in stock - Investing.com
Thu, 29 Jan 2026
Nanovibronix (FEED) Stock Price, News & Analysis $FEED - MarketBeat
Fri, 12 Dec 2025
NanoVibronix to rebrand as ENvue Medical, trade under FEED symbol - Investing.com
Wed, 19 Nov 2025
NanoVibronix to rebrand as ENvue Medical, focuses on feeding tube tech - Investing.com
Tue, 16 Sep 2025
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Thu, 24 Apr 2025
NAOV Stock Price, News & Analysis - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 860380 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 89 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.084e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 173 % |
| Return on Equity (ttm) | -32.8 % |
| Qtrly Rev. Growth | 2.55e+006 % |
| Gross Profit (p.s.) | -14.15 |
| Sales Per Share | -50.76 |
| EBITDA (p.s.) | 72857.1 |
| Qtrly Earnings Growth | -26.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.05 |
| Dividend | 0 |
| Forward Dividend | 16230 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|